Extended Data Fig. 2: Tamoxifen does not interfere in metabolic syndrome induced by MSG.
A) Representative western blot in liver for AMPD2 (top) and actin loading control (bottom) in tamoxifen-resistant AMPD2Fl/FL mice and tamoxifen-inducible AMPD2 knockout mice (AMPD2Fl/FLxCre-UBC) at days 0, 5 and 12 after tamoxifen treatment. B) Seven hour food intake in AMPD2Fl/FL (black) and AMPD2Fl/FLxCre-UBC (red) mice before (weeks 0 to week 7) and after (week 7 to week 15) tamoxifen (TMX) treatment C) MSG solution drinking in the same groups as in B) D) Body weight gain in in the same groups as in B) E) Fat/fat free mass ratio in in the same groups as in B) F) Fasting plasma insulin in AMPD2Fl/FL (black) and AMPD2Fl/FLxCre-UBC (red) mice at baseline (week 0), before TMX treatment (week 7) and after TMX treatment (week 15). G) Fasting plasma leptin levels in the same groups as in G). H) Leptin sensitivity in AMPD2Fl/FL mice at baseline (week 0), and after TMX treatment (weeks 9 and 15). I) Leptin sensitivity in AMPD2Fl/FLxCre-UBC mice at baseline (week 0), before TMX treatment (weeks 9 and 15). Data in F-G represent individual points with mean ± SEM. Data in B-E represent mean ± SEM. Data in H-I represent the mean. One Way ANOVA (F-G) and 2-tail t-test (A-E and H-I). N = 6 mice per group.
